{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"0.941","upperLimit":"2.279","value":"1.61"},{"groupId":"OG004","lowerLimit":"0.909","upperLimit":"2.115","value":"1.866"},{"groupId":"OG005","lowerLimit":"0.493","upperLimit":"4.143","value":"2.306"},{"groupId":"OG006","lowerLimit":"0.502","upperLimit":"11.122","value":"5.158"},{"groupId":"OG007","lowerLimit":"1.147","upperLimit":"2.189","value":"1.416"},{"groupId":"OG008","lowerLimit":"0.429","upperLimit":"2.819","value":"1.572"},{"groupId":"OG009","lowerLimit":"0.688","upperLimit":"2.327","value":"1.508"},{"groupId":"OG010","lowerLimit":"1.434","upperLimit":"3.482","value":"2.252"},{"groupId":"OG011","lowerLimit":"0.548","upperLimit":"2.160","value":"1.354"},{"groupId":"OG012","lowerLimit":"1.428","upperLimit":"3.592","value":"1.772"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"17"}],"units":"Participants"}],"description":"Progression-free survival is the time from first study dose until disease progression (PD; target lesion increase of 20% and at least 5mm from smallest on-study lesion sum, the appearance of new lesions, or unequivocal progression of non-target lesions) per RECIST v1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who received doses at 25 mg once daily under fasted conditions.","id":"OG000","title":"Dose Escalation 25 mg QD"},{"description":"Patients who received doses at 50 mg once daily under fasted conditions.","id":"OG001","title":"Dose Escalation 50 mg QD"},{"description":"Patients who received doses at 100 mg once daily under fasted conditions.","id":"OG002","title":"Dose Escalation 100 mg QD"},{"description":"Patients who received doses at 200 mg once daily under fasted conditions.","id":"OG003","title":"Dose Escalation 200 mg QD"},{"description":"Patients who received 400 mg once daily under fasted conditions.","id":"OG004","title":"Dose Escalation 400 mg QD"},{"description":"Patients who received 800 mg once daily under fasted conditions.","id":"OG005","title":"Dose Escalation 800 mg QD"},{"description":"Patients who received 800 mg once daily under not fasted conditions.","id":"OG006","title":"Dose Escalation 800 mg QD NF"},{"description":"Patients who received 1000 mg once daily under not fasted conditions","id":"OG007","title":"Dose Escalation 1000 mg QD"},{"description":"Patients who received 1200 mg once daily under fasted conditions.","id":"OG008","title":"Dose Escalation 1200 mg QD"},{"description":"Patients who received 400 mg twice daily under not fasted conditions.","id":"OG009","title":"Dose Escalation 400 mg BID"},{"description":"Patients who received 600 mg twice daily under not fasted conditions.","id":"OG010","title":"Dose Escalation 600 mg BID"},{"description":"Patients who received 800 mg twice daily under fasted conditions.","id":"OG011","title":"Dose Escalation 800 mg BID"},{"description":"Patients in safety expansion who received 800 mg once daily under not fasted conditions.","id":"OG012","title":"Safety Expansion 800 mg QD"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Assessed until disease progression or death for up to 12 months","title":"Phase 1: Progression-free Survival as a Measure of Antitumor Activity","type":"SECONDARY","unitOfMeasure":"Months"}